Agelastatin A: A novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 548-558

  Mason, Charlene K ^a   McFarlane, Suzanne ^a   Johnston, Patrick G ^a   Crowe, Paul ^a   Erwin, Pauline J ^a   Domostoj, Mathias M ^b   Campbell, F Charles ^a   Manaviazar, Soraya ^a   Hale, Karl J ^a   El Tanani, Mohamed ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGELASTATIN A; ANTINEOPLASTIC AGENT; BETA CATENIN; OSTEOPONTIN; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL ADHESION; CELL CYCLE G2 PHASE; CELL INVASION; CELL LINE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; UPREGULATION;

ALKALOIDS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOPONTIN; OXAZOLIDINONES; PROMOTER REGIONS (GENETICS); RNA INTERFERENCE;

EID: 41649087976     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2251     Document Type: Article

References (53)

1. Kamby C. The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. Cancer Treat Rev 1990;17:37-61.
2. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002;62:3417-27.
3. El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 2001;61:5619-29.
4. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
5. Polakis P. The oncogenic activation of β-catenin. Curr Opin Genet Dev 1999;9:15-21.
6. Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 2004;5:91-102.
7. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
8. Nagai S, Hashimoto S, Yamashita T, et al. Comprehensive gene expression profile of human activated T(h)1- and T(h)2-polarized cells. Int Immunol 2001;13:367-76.
9. Muller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp Cell Res 2002;280:119-33.
10. Jimeno J, Aracil M, Tercero JC. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med 2006;4:3.
11. D'Ambrosio M, Guerriero A, Debitus C, et al. Agelastatin A, a new skeleton cytotoxic alkaloid of the oroidin family. isolation from the axinellid sponge Agelas dendromorpha of the coral sea. J Chem Soc Chem Commun 1993:1305.
12. Guerriero A, D'Ambrosio M, Chiasera G, Pietra F. Conformational preferences of agelastatin A, a cytotoxic alkaloid of the axinellid sponge Agelas dendromorpha from the coral sea, via combined molecular modeling, NMR and exciton splitting for diamide and hydroxyamide derivatives. Helvetica Chimica Acta 1994;79:1895-902.
13. D'Ambrosio M, Guerriero A, Ripamonti M, Debitus C, Waikedre J, Pietra F. The active centres of agelastatin A, a strongly cytotoxic alkaloid of the coral sea axinellid sponge Agelas dendromorpha, as determined by comparative bioassays with semisynthetic derivatives. Helvetica Chimica Acta 1996;79:727-35.
14. Pettit GR, Ducki S, Herald DL, Doubek DL, Schmidt JM, Chapuis JC. Absolute configuration of the marine sponge bromopyrrole agelastatin A. Oncol Res 2005;15:11-20.
15. Hale KJ, Domostoj MM, El-Tanani M, Campbell FC, Mason CK. Total synthesis and mechanism of action studies on the antitumour alkaloid, (-)-agelastatin A. In: Harmata M, editor. Strategies and tactics in organic synthesis. London: Academic Press; 2005. p. 352-94.
16. Domostoj MM, Irving E, Scheinmann F, Hale KJ. New total synthesis of the marine antitumor alkaloid (-)-agelastatin A. Org Lett 2004;6:2615-8.
17. Dunnington DJ, Hughes CM, Monaghan P, Rudland PS. Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst 1983;71:1227-40.
18. Oates AJ, Barraclough R, Rudland PS. The identification of metastasis-related gene products in a rodent mammary tumour model. Biochem Soc Trans 1996;24:353S.
19. El-Tanani MK, Campbell FC, Crowe P, et al. BRCA1 suppresses osteopontin-mediated breast cancer. J Biol Chem 2006;281:26587-601.
20. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with β-catenin-Lef-1 and c-jun in regulation of osteopontin transcription. J Biol Chem 2004;279:20794-806.
21. Moye VE, Barraclough R, West C, Rudland PS. Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 2004;90:1796-802.
22. El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland P. Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors. J Biol Chem 2001;276:41675-82.
23. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
24. Boyer J, McLean EG, Aroori S, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10:2158-67.
25. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7:1475-82.
26. Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 1999;7:103-13.
27. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61.
28. Hannon GJ. RNA interference. Nature 2002;418:244-51.
29. Lieberman J, Song E, Lee SK, Shankar P. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 2003;9:397-403.
30. de Silva Rudland S, Martin L, Roshanlall C, et al. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006;12:1192-200.
31. Mariadason JM, Bordonaro M, Aslam F, et al. Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 2001;61:3465-71.
32. Sharp JA, Sung V, Slavin J, Thompson EW, Henderson MA. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 1999;79:869-77.
33. Wadlow R, Finley SA, Ramaswamy S. Genome-wide views of cancer metastasis. Drug Discov Today Dis Mech 2005;2:165-9.
34. Ohlsson R, Kanduri C, Whitehead J, Pfeifer S, Lobanenkov V, Feinberg AP. Epigenetic variability and the evolution of human cancer. Adv Cancer Res 2003;88:145-68.
35. Lin SY, Xia W, Wang JC, et al. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000;97:4262-6.
36. Mann B, Gelos M, Siedow A, et al. Target genes of β-catenin-T cell factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-8.
37. + thymocytes regulate proliferation and cell adhesion. J Immunol 2004;172:1099-1108.
38. Crawford HC, Fingleton B, Gustavson MD, et al. The PEA3 subfamily of Ets transcription factors synergizes with β-catenin-LEF-1 to activate matrilysin transcription in intestinal tumours. Mol Cell Biol 2001;21:1370-83.
39. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6:556-68.
40. Xing Y, Clements WK, Kimelman D, Xu W. Crystal structure of a β-catenin/axin complex suggests a mechanism for the β-catenin destruction complex. Genes Dev 2003;17:2753-64.
41. Liu C, Kato Y, Zhang Z, Do VM, Yankner BA, He X. β-TRCP couples β-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A 1999;96:6273-8.
42. Cheyette BN, Waxman JS, Miller JR, et al. Dapper, a disheveled-associated antagonist of β-catenin and JNK signaling, is required for notochord formation. Dev Cell 2002;2:449-61.
43. Duan L, Yao J, Wu X, Fan M. Growth suppression induced by Notch1 activation involves Wnt-β-catenin down-regulation in human tongue carcinoma cells. Biol Cell 2006;98:479-90.
44. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001;353:417-39.
45. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. Aberrant β-catenin signaling in tuberous sclerosis. Am J Pathol 2005;167:107-16.
46. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. The tuberin-hamartin complex negatively regulates β-catenin signaling activity. J Biol Chem 2003;278:5947-51.
47. Plateroti M, Kress E, Mori JI, Samarut J. Thyroid hormone receptor alpha1 directly controls transcription of the β-catenin gene in intestinal epithelial cells. Mol Cell Biol 2006;26:3204-14.
48. Morin PJ. β-catenin signaling and cancer. Bioessays 1999;21:1021-30.
49. Zhang GX, Zhao ZQ, Wang HD, Hao B. Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World J Gastroenterol 2004;10:205-8.
50. Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/β-catenin pathway in liver. Gastroenterology 2005;129:285-302.
51. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/β-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-6.
52. Min/+ mice. Cancer Res 2003;63:895-901.
53. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.